<DOC>
	<DOCNO>NCT01679899</DOCNO>
	<brief_summary>This Monocentric , Prospective , Randomized , Open-label , Comparative , Phase IV Study , compare effect Vildagliptin Gliclazide MR Markers Bone Remodeling , Bone Mineral Density Glycemic Variability Postmenopausal Women Type 2 Diabetes . A total 38 woman document Type 2 Diabetes menopause enrol . The active treatment include 50 mg dose vildagliptin OD twice day . As comparator , gliclazide MR administer dose 60 120 mg OD day .</brief_summary>
	<brief_title>Effect Anti-diabetic Drugs Bone Metabolism Glycemic Variability</brief_title>
	<detailed_description>This Monocentric , Prospective , Randomized , Open-label , Comparative , Phase IV Study , compare effect Vildagliptin Gliclazide MR Markers Bone Remodeling , Bone Mineral Density Glycemic Variability Postmenopausal Women Type 2 Diabetes . Target population clinical trial subject A total 38 woman document Type 2 Diabetes menopause enrol . To close real life scenario possible , clinical trial subject treat glucose-lowering medication ( except incretin sulfonylurea base therapy ) treatment-naive subject include . Investigational Product , posology method administration The active treatment include 50 mg dose vildagliptin OD twice day . Comparator , posology method administration As comparator , gliclazide MR administer dose 60 120 mg OD day . Treatment duration The study expect total duration 18 month , 12 month active treatment .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Gliclazide</mesh_term>
	<criteria>Informed consent form obtain studyrelated activity . Studyrelated activity procedure would perform normal treatment patient . All study subject must woman diagnose type 2 diabetes base current guideline Sociedade Brasileira de Diabetes ( SBD Brazilian Society Diabetes ) and/or American Society Diabetes ( ADA ) follow criterion : Age ≥ 40 year old . HbA1c ≥ 6.5 % randomization . Menopause define : Absence menstruation least 12 month patient intact uterus , FSH level great 30 mIU/mL hysterectomized patient and/or , FSH level great 30 mIU/mL patient surgical menopause . Acute vascular event ( cardiac , cerebral peripheral ) least 2 month randomization . Patient chronic dialysis and/or renal transplantation and/or serum creatinine &gt; 1.5 mg/dL . Patients HIV , severe autoimmune disease chronic treatment oral steroid ( &gt; 30 consecutive day ) . Current previous treatment ( within 6 month ) incretin ( DPPIV inhibitor GLP1 analog ) within 6 month prior randomization . Current previous treatment pioglitazone rosiglitazone within 12 month prior randomization . Sustained arterial hypertension &gt; 180/100 mm Hg . Body mass index ( BMI ) &gt; 50 kg/m² . HbA1c ≥ 9,5 % randomization . Transaminases ( AST ( SGOT ) ALT ( SGPT ) ) &gt; 2.5 x upper limit normal . Chronic liver disease alcoholic liver disease . LDLcholesterol &gt; 250 mg/dL ( &gt; 6.48 mmol/L ) . Triglycerides &gt; 1000 mg/dL ( &gt; 11.3 mmol/L ) . HDLcholesterol &lt; 25 mg/dL ( &lt; 0.64 mmol/L ) . Levels 25OHvitamin D &lt; 20ng/mL randomization Abnormal level PTH , cortisol , IGF1 GH randomization Prescription investigational medication within one year screen visit ( visit 1 ) , unless direct benefit study subject , discretion investigator . History previous fracture Pregnant breastfeeding patient . Previous participation study . Individuals risk poor adherence protocol medication . Any condition make patient unable complete study within 12 month .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>diabetes</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>osteopenia</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>glycemic variability</keyword>
	<keyword>bone marker</keyword>
	<keyword>osteocalcin</keyword>
	<keyword>NTX</keyword>
	<keyword>CTX</keyword>
	<keyword>BALP</keyword>
</DOC>